AstraZeneca presented its report on the clinical trials of MEDI4736 at the annual American Society of Clinical Oncology (ASCO) conference in Chicago.
It is a type of medicine that obstructs the formation of tumor by restricting its activities against the defenses of immune system. This type of drug is popular as anti-PDL1 therapies.
AstraZeneca has reported that the drug has shown responsiveness in multiple types of cancer such as cutaneous melanoma, pancreatic cancer, squamous cell carcinoma of head and neck, cancer and non-small lung cancer.
During the Phase I clinical trials conducted on 27 patients, it was found that the drug has produced noticeable effects in the patients of colorectal cancer, non-small cell lung cancer and it has even been a good option for melanoma cancer treatment.
On the other hand, tumor shrinkage was viewed in 19 percent patients, and 39 percent patients had steadied cancer after one year of treatment.